

# THE RENAISSANCE ERA OF LUNG CANCER THERAPIES

## LUNG CANCER EUROPEAN MEETING (LuCE-M)

CME ID 2157-229486

The International Congress "LUCEM THE RENAISSANCE ERA OF LUNG CANCER THERAPIES Lung Cancer European Meeting-(LUCEM 2)" is credited for up to 100 participants and has been awarded for the following professions: **medical surgeon (all disciplines), healthcare assistant, biologist and nurse**. The credits (**8 assigned**) will be provided with a complete participation in scientific work and learning exam with at least 75% of correct answers.

### Inscription

Membership is free and entitles you to participation in Congress, Conference kit, certificate of attendance, coffee-break and lunch buffet. To enroll, send your personal data (name, surname, telephone number, e-mail), to the following address email: [info@medicacom.it](mailto:info@medicacom.it), or at the following **fax number: 02 93661995**. For organizational purposes, entries must be received by July 4<sup>th</sup>, 2018.

### CHAIRMAN

**Diego Luigi Cortinovis:** Medical Oncology Unit, ASST Monza, San Gerardo Hospital, Italy

### FACULTY

**Francesco Agustoni:** Medical Oncology Unit, ASST Monza, San Gerardo Hospital, Italy

**Paolo Bidoli:** S.C. Medical Oncology Unit, ASST Monza, San Gerardo Hospital, Italy

**Ramesh Bulusu:** Consultant Oncologist and UK Lead Clinician for PAWS GIST Clinic

**Raffaele Califano:** Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom

**Stefania Canova:** Medical Oncology Unit, ASST Monza, San Gerardo Hospital, Italy

**Francesca Colonese:** Medical Oncology Unit, ASST Monza, San Gerardo Hospital, Italy

**Jesus Corral:** Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain

**Matteo Giaj Levra:** Medical Oncology Unit and Thoracic Oncology, Centre hospitalo-universitaire de Grenoble Hôpital Michallon, France

**Ignacio Gil Bazo:** Medical Oncology Department, Clínica Universidad de Navarra Center for Applied Medical Research, Pamplona, Spain

**Niki Karachaliou:** University Hospital Sagrat Cor Instituto Oncológico Rosell (IOR), Barcelona, Spain

**Zoltan Lohinai:** Medical Pulmonary Oncology, Koranyi Institute of Pulmonology, Budapest, Hungary

**Marcus Pantarotto:** Medical Oncology, Hospital Da Luz, Lisbona, Portugal

**Niels Reinmuth:** Thoracic Oncology Department at the Asklepios Lung Clinic in Munich-Gauting, Germany

**Marco Scarci:** Thoracic Surgery Unit, ASST Monza, San Gerardo Hospital, Italy

**Justin Stebbing:** Professor of Cancer Medicine and Oncology Consultant Oncologist, Imperial College and Imperial College Healthcare NHS Trust, London, United Kingdom

**Marcello Tiseo:** Medical Oncology, A.O.U. Parma, Italy

**Anne Claire Toffart:** Associate Professor, Clinique de Pneumologie, Pôle Thorax et Vaisseaux, CHU Grenoble Alpes, France

**Luca Toschi:** Oncology and Hematology Department, Humanitas Cancer Center, IRCCS Rozzano, Milano, Italy

### PATRONAGE ON REQUEST:



Secondo le finalità  
della Rete  
Oncologica Regionale



With the unrestricted grant of:



With the presence of:



# THE RENAISSANCE ERA OF LUNG CANCER THERAPIES

## LUNG CANCER EUROPEAN MEETING (LuCE-M)

**Friday, July 6<sup>th</sup>, 2018**

Congress Center, San Gerardo Hospital, Monza

### Chairman

Dr. Diego Cortinovis

Provider CME, Scientific and Organizational Secretariat

**Medica**  
EDITORIA E  
DIFFUSIONE  
SCIENTIFICA

Medica Editoria e Diffusione Scientifica  
Corso Buenos Aires, 43 - 20124 Milano  
Tel +39 02 7628 1337 - Fax +39 02 9366 1995  
[info@medicacom.it](mailto:info@medicacom.it)

**Medica**  
EDITORIA E  
DIFFUSIONE  
SCIENTIFICA

Provider CME, Scientific and Organizational Secretariat



# THE RENAISSANCE ERA OF LUNG CANCER THERAPIES

## LUNG CANCER EUROPEAN MEETING (LuCE-M)

### SCIENTIFIC RATIONALE

The therapeutic pathways in managing non-small cell lung cancer are now extremely complex and articulated and start from a basic biomolecular evaluation. This evaluation aims to provide the clinician with the tools needed for precision medicine.

Immunotherapy are nowadays a cornerstone in therapeutic strategy from first line setting making 20% of lung cancer a true chronic disease, however little is known in clinical practice about overcoming the resistance to antiPD1 and antiPDL1 agents.

Antiangiogenic therapies become valuable-allies in the fight against this type of cancer. The availability and applicability in clinical practice can create long-term survivors following this diagnosis.

A better knowledge about the clonal evolution of cancer together the understanding of links with microenvironment makes lung cancer a model to discover new ways to harness its devastating behaviour.

These aspects are further corroborated by the clinical research and networks.

The international collaboration between clinicians and investment in biomolecular platforms are the key to truly effective and powerful research needed to ensure optimal targeted therapy for each tumor.

### AGENDA

#### THE RENAISSANCE ERA OF LUNG CANCER THERAPIES

*D. Cortinovis (Chairman)*

**10.00 Welcome and introduction:**  
*D. Cortinovis, P. Bidoli, M. Scarci (Moderator)*

#### FIRST SESSION: THE MIDDLE AGE

*D. Cortinovis, L. Toschi (Moderator)*

**10.15 The role of chemotherapy in 2018:**  
is there already a place?  
*J. Corral*

**10.35 Discussion corner**  
*All*

**10.50 Pharmacogenomics and epigenetics:**  
new discoveries of old fashion Cts  
*N. Reinmuth*

**11.10 Discussion corner**  
*All*

**11.25 Antiangiogenic agents:**  
Folkman's promise or Morgana effect  
*A. C. Toffart*

**11.45 Discussion corner**  
*All*

**12.00 Lecture: Lung cancer clonal heterogeneity**  
and application in early disease detection  
*J. Stebbing*

**12.30 LUNCH**

#### SECOND SESSION: THE RENAISSANCE

*P. Bidoli (Moderator)*

**13.00 Immune breaking news in first and further lines**  
*R. Bulusu*

**13.20 Discussion corner**  
*All*

**13.35 Micro-environment manipulation:**  
predictive factors of ICI activity  
*R. Califano*

**13.55 Discussion corner**  
*All*

**14.10 EGFR TKI: the winner is....**  
*N. Karachaliou*

**14.40 Discussion corner**  
*All*

**14.55 ALK TKI: the winner is.....**  
*M. Pantarotto*

**15.25 Discussion corner**  
*All*

**15.40 An interactive clinical case**  
*F. Colonese, F. Agustoni*

#### THIRD SESSION: POST-ATOMIC AGE

*S. Canova, M. Tiseo (Moderator)*

**16.10 Immune combos: IO+IO or CT+IO?**  
*Z. Lohinai*

**16.30 Discussion corner**  
*All*

**16.45 Targeted agents over the resistance mechanisms**  
*I. Gill Bazo*

**17.10 Discussion corner**  
*All*

**17.25 The sustainability of new drugs**  
*M. Giaj Levra*

**17.45 Final Discussion:**  
Open my mind: drawing new therapeutic algorithm  
*All*

**18.30 Closing Remarks and final test CME**